Short Interest in Biora Therapeutics, Inc. (NASDAQ:BIOR) Expands By 27.9%

Biora Therapeutics, Inc. (NASDAQ:BIOR) was the recipient of a significant increase in short interest in November. As of November 15th, there was short interest totalling 258,100 shares, an increase of 27.9% from the October 31st total of 201,800 shares. Based on an average daily trading volume, of 68,700 shares, the days-to-cover ratio is presently 3.8 days. Approximately 5.9% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their target price on Biora Therapeutics from $15.00 to $23.00 and gave the company a “buy” rating in a report on Monday, November 18th.

Biora Therapeutics Stock Up 1.0 %

NASDAQ:BIOR traded up $0.02 on Friday, hitting $1.95. The stock had a trading volume of 35,750 shares, compared to its average volume of 43,963. The company has a fifty day moving average price of $3.79 and a two-hundred day moving average price of $5.65. Biora Therapeutics has a 1-year low of $1.43 and a 1-year high of $19.90. The stock has a market cap of $8.82 million, a price-to-earnings ratio of -0.15 and a beta of 1.27.

About Biora Therapeutics

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.